STOCK TITAN

MiMedx Board Member Grows Stake to 212,000 Shares in Latest Stock Award

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MiMedx Group director James L. Bierman acquired 28,609 shares of common stock on June 18, 2025 at a price of $6.47 per share, bringing his total direct holdings to 212,771 shares.

The acquisition represents an annual restricted stock grant to non-employee directors and is exempt under Rule 16b-3. The awarded shares will vest upon the earlier of:

  • 12 months from grant date
  • The next annual meeting of shareholders

The Form 4 filing was signed by William F. Hulse as attorney-in-fact for Bierman on June 23, 2025. This transaction demonstrates continued alignment of director interests with shareholders through equity-based compensation.

Positive

  • None.

Negative

  • None.
Insider BIERMAN JAMES L
Role Director
Type Security Shares Price Value
Grant/Award Common Stock 28,609 $6.47 $185K
Holdings After Transaction: Common Stock — 212,771 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BIERMAN JAMES L

(Last) (First) (Middle)
1775 WEST OAK COMMONS COURT

(Street)
MARIETTA GA 30062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MIMEDX GROUP, INC. [ MDXG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/18/2025 A 28,609(1) A $6.47 212,771 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents annual restricted stock grant to non-employee directors. Grant is exempt under Rule 16b-3. The award vests upon the earlier of 12 months or the next annual meeting of shareholders
Remarks:
/s/ William F. Hulse as attorney in fact for James L. Bierman 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MDXG shares did Director James Bierman acquire on June 18, 2025?

Director James Bierman acquired 28,609 shares of MDXG common stock on June 18, 2025, as part of an annual restricted stock grant to non-employee directors at a price of $6.47 per share.

What is the vesting period for MDXG's director stock grants in 2025?

The restricted stock grant for MDXG's non-employee directors vests upon the earlier of 12 months or the next annual meeting of shareholders. This grant was made under Rule 16b-3 exemption.

How many MDXG shares does James Bierman own after the June 2025 stock grant?

Following the restricted stock grant transaction, James Bierman beneficially owns 212,771 shares of MDXG common stock directly (Form: Direct Ownership).

Did MDXG Director James Bierman purchase or receive these shares as compensation?

The shares were received as compensation, specifically as an annual restricted stock grant to non-employee directors. The Form 4 indicates this was a grant exempt under Rule 16b-3, which typically applies to equity compensation awards.